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Objectives: Our objective was to demonstrate microbial regulation of hepatic genes 43 
implicated in drug metabolism and transport using germ-free (GF) mice and to explore the 44 
impact of a microbial metabolite, butyrate, and a prebiotic dietary intervention on hepatic 45 
gene expression in mice. 46 
Methods: Using reverse-transcriptase PCR, we investigated cytochrome P450 (CYP) and 47 
multidrug-resistance protein 1 (MDR1) expression in conventional, GF, and colonised GF 48 
mice. To investigate the effects of butyrate, sodium butyrate (3 g/L) was administered for 21 49 
days to conventional or GF mice. In the prebiotic study, young-adult and middle-aged mice 50 
received diet-enriched with 10% fructo-oligosaccharide (FOS)-inulin for 14 weeks.  51 
Key findings: Colonisation of GF animals normalised expression of Cyp3a11 and Mdr1b to 52 
conventional levels. Butyrate upregulated Cyp2b10 in conventional mice (p<0.05) but overall 53 
did not induce widespread changes in hepatic genes. FOS-inulin increased Cyp3a13 54 
expression and had the opposite effect on Mdr1a expression in young-adult mice (p<0.05). 55 
Age, on the other hand, influenced the prebiotic effect on Cyp2a4 expression (p<0.01). 56 
Conclusion: The expression of hepatic genes implicated in drug metabolism and transport 57 
displays sensitivity to the microbiome, microbiome-derived metabolites, and a microbial-58 
targeted intervention. Our study may provide the impetus to explore microbiota-targeted 59 
interventions in normalising host metabolic activity and reducing inter-individual variability 60 
in drug pharmacokinetics. 61 
Keywords: Microbiome, Cytochrome, Transporter, Hepatic, Drug, Metabolism 62 
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Introduction  63 
The metabolic fate and toxicity of drugs are determined, in part, by the expression of drug-64 
metabolising enzymes and drug transporters (1). In particular, the cytochrome P450 (CYP) 65 
enzyme superfamily and drug-efflux transporters are key drivers of oral drug bioavailability 66 
(2). Drug-efflux transporters, including multidrug-resistance protein 1 (MDR1), expel 67 
conjugated drugs from the liver into the bile ducts and thus make an essential contribution to 68 
drug pharmacokinetics (3). Significantly, CYP1-3 family members are implicated in the 69 
metabolism of 70-80% of all drugs in clinical use (4) and MDR1, also known as P-70 
glycoprotein (P-gp), is an efflux pump with broad substrate specificity (2). While humans 71 
express a single MDR1 gene, rodents share the function of hepatic MDR1 between two 72 
highly homologous MDR1-type genes, Mdr1a and Mdr1b (5, 6).  73 
Inter-individual variability in the expression of CYP genes is generally linked to age, race, 74 
genetics, concomitant disease, or co-administered drugs (4). However, the importance of the 75 
gut microbiota, the trillions of micro-organisms residing along the gastrointestinal tract (7), 76 
has recently come to the fore as an additional variable adding to this complexity. Evidence 77 
from germ-free (GF) mice, mice devoid of microbes, demonstrate altered expression of 78 
hepatic genes implicated in drug metabolism (8-10). The drug-metabolising capacity of an 79 
individual may vary, therefore, not only because of polymorphisms in genes encoding host 80 
drug-metabolising enzymes and the concomitant intake of drugs but also due to individual 81 
differences in the composition of the gut microbiota. This interconnectivity between the 82 
intestinal tract and the liver makes it essential to view drug metabolic processes as co-83 
metabolism by the host and the gut microbiota (11). 84 
The liver receives approximately 70% of its blood supply from the intestine and is thus 85 
continually exposed to microbial metabolites, including short-chain fatty acids (SCFA) (12). 86 
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One such SCFA, butyrate, is efficiently metabolised by the intestinal epithelial cells, but a 87 
proportion is absorbed and transported into the liver by the portal vein (13). Evidence 88 
suggests that butyrate can induce Cyp1a2 expression possibly linked to the modification of 89 
histones (14, 15). However, whether this effect is dependent on an intact gut microbiome or 90 
affects the expression of other CYP genes is unknown. 91 
The impact of microbiota-targeted therapies, including antibiotics, probiotics (i.e., “live 92 
microorganisms which when administered in adequate amounts confer a health benefit on the 93 
host” (16)), and prebiotics (i.e., “a substrate that is selectively utilized by host 94 
microorganisms conferring a health benefit” (17)) on CYP and MDR1, and their potential 95 
knock-on effects on the response to co-administered medication (18), is a significant but 96 
underexplored area of drug metabolism. While there are several reports that a change in 97 
nutritional status affects hepatic levels of drug-metabolising enzymes (19), a commercially 98 
available probiotic mix, VSL#3, exerted a limited effect on CYP gene expression (8). 99 
Modulation of intestinal microbes by prebiotics may also, however, alter the drug-100 
metabolising capacity of the host. Foods such as onions, leeks, and garlic are dietary sources 101 
of the prebiotic inulin (20), which protects against high-fat diet-induced alterations in both 102 
the expression and activity of Cyp1a1, Cyp1a2, and Cyp2e1 (19).  103 
Here, we aimed to further validate the role of the gut microbiota in the regulation of CYP 104 
drug-metabolising enzymes and the drug-efflux transporter, MDR1. The microbial 105 
metabolite, butyrate, was investigated as a potential influencer of these host-microbe 106 
interactions. We further examined the impact of fructo-oligosaccharide-inulin (FOS-inulin), a 107 
dietary prebiotic known to alter the composition and function of the gut microbiome (21), on 108 
hepatic gene expression at different life-stages. 109 
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Materials and Methods  110 
 111 
All experiments were conducted in accordance with the European Directive 86/609/EEC and 112 
the Recommendation 2007/526/65/EC. Ethical approval for each study was obtained from the 113 
Animal Experimentation Ethics Committee of University College Cork before the 114 
commencement of all animal-related experiments. For the impact of the GF/colonisation 115 
study, ethical approval (AE19130/P047) was granted on 16/02/2017. For the butyrate 116 
supplementation study, ethical approval (AE19130/P023) was granted on 13/01/2016. For the 117 
FOS-inulin intervention study, ethical approval (B100/3774) was issued on 18/12/2012. 118 
 119 
Animals  120 
Male F1-generation offspring from conventionally raised and GF C57BL/6J breeding pairs 121 
(Taconic, Germantown, New York, USA) were used as previously described (22). GF mice 122 
were housed in specific isolators. Animals were kept under a 12-h light/dark cycle, with a 123 
temperature of 21 ± 1 °C and humidity of 55 ± 10%. Food and water were given ad libitum. 124 
Conventional, GF, colonised GF, and butyrate-treated mice were fed an autoclaved diet 125 
(Special Diets Services, UK). See FOS-inulin study for corresponding diet and animal 126 
information. 127 
 128 
GF/Colonisation Study 129 
At postnatal day 21, a subset of GF mice were transferred to the conventional animal facility 130 
and were colonised by exposure to used cage bedding of age-, vendor- and sex-matched 131 
7 
 
conventional mice for 7-8 weeks. Mice were euthanised by decapitation, and liver samples 132 
were immediately snap-frozen and stored at -80 oC until further analysis.  133 
Butyrate Study  134 
Sodium butyrate (3 g/L; Sigma-Aldrich), or sodium chloride for sodium-matched controls, 135 
was dissolved in sterile drinking water and administered for 21 days to conventional or GF 136 
male C57BL/6 mice (n=13-15/group). This dosage was based on previous studies by our 137 
research group and others investigating the impact of butyrate (600 mg/kg) on behaviour in 138 
mice, combined with an estimated drinking water consumption of 5 ml/day (23-25). Drinking 139 
water was filtered through a 0.2-micron syringe filter (Sarstedt) and refreshed twice per week. 140 
As diet can contribute to the gastrointestinal and systemic levels of butyrate in vivo, food 141 
intake was closely monitored across all experimental groups and no significant differences in 142 
food consumption were observed. Mice were euthanised by decapitation, and liver samples 143 
were immediately snap-frozen and stored at -80 oC until further analysis.  144 
 145 
FOS-Inulin Study 146 
Previous work by our laboratory investigated prebiotic supplementation (FOS-Inulin) on the 147 
peripheral immune response and neuroinflammation in middle age (21). Here, we sought to 148 
examine the effects of prebiotic supplementation on hepatic gene expression from tissues 149 
collected from the same animals. In brief, young adult (approx. 2 months at start of treatment) 150 
and middle-aged (approx. 10 months at start of treatment) conventional male C57BL/6 mice 151 
(obtained from Harlan, Cambridgeshire) received a standard diet (ssniff-Spezialdiäten 152 
GmbH, Soest, Germany) or the diet enriched with 10% Oligofructose-enriched inulin (FOS-153 
Inulin: mixture of 92±2% Inulin and 8±2% Fructo-oligosaccharide, Orafti®Synergy1; 154 
BENEO-Orafti N.V., Belgium) for 14weeks (n=9-10/group). Mice were euthanised by 155 
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decapitation, and liver samples were immediately snap-frozen and stored at -80 oC until 156 
further analysis.  157 
 158 
RNA extraction, Reverse transcription and RT-qPCR  159 
Total RNA was isolated from harvested liver tissue using the High Pure RNA Tissue Kit 160 
(Sigma Aldrich) following the manufacturer’s protocol or using the mirVanaTM miRNA 161 
Isolation Kit (Thermo Scientific/Invitrogen; GF/Colonisation study). Tissue from the 162 
GF/Colonisation study required the use of an RNA extraction kit well-suited for total and 163 
miRNA isolation suitable for future downstream miRNA analyses. Both kits allowed for the 164 
comparable high-quality, pure, intact collection of RNA used in the present study. Following 165 
RNA extraction, RNA concentration and quality were determined using the standard 166 
OD260/280 method using a Nanodrop spectrophotometer (Thermo Scientific). The 167 
OD260/OD280 ratio for each RNA sample used in subsequent experiments was in the range 168 
1.9-2.1. RNA was reversed transcribed to cDNA using the Exiqon cDNA Universal Synthesis 169 
kit (Exiqon A/Q) or High Capacity cDNA Reverse Transcription kit (Thermo 170 
Scientific/Applied Biosystems) in a G-storm thermocycler (G-storm, Surrey, UK).  171 
Reverse-transcriptase PCR was employed to compare the mRNA expression of CYP drug-172 
metabolising enzymes and the two mouse isoforms of hMDR1, Mdr1a, and Mdr1b. The most 173 
commonly studied CYP and MDR murine isoforms equivalent to humans are described in 174 
Table.1. [see Table 1] 175 
While the murine isoforms of hMDR1 show differential distribution in other physiological 176 
areas, both Mdr1a and Mdr1b are widely distributed in the liver (26). There are, however, 177 
some inter-species differences in CYP and MDR genes in mice and humans, in terms of 178 
sequence homology and substrate specificity (27). 179 
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For the GF/colonisation study, RT-qPCR was performed using TaqMan Universal Master 180 
Mix II (Thermo Fisher Scientific/Applied Biosystems), and genes of interest were amplified 181 
using TaqMan probes (Integrated DNA Technologies). For the RT-qPCRs from the butyrate- 182 
or FOS-inulin study liver samples, SYBR Green detection chemistry was employed, utilising 183 
the ExiLENT SYBRR GREEN Master Mix (Exiqon A/Q) or SensiFAST SYBR Lo-ROX kit 184 
(Bioline) respectively. SYBR Green compatible primers were obtained from Eurofins 185 
Genomics, and the primer oligosaccharide sequences are detailed in the supplementary 186 
material (Table S1). Reactions were run in GeneAMP PCR System 9700 (Applied 187 
Biosystems). Each transcript value was calculated as the average of at least duplicate samples 188 
across experimental conditions. Values were normalised to β-actin as the housekeeping gene 189 
whose expression was stable under these experimental conditions. Data were analysed with 190 
the comparative cycle threshold method (2-ΔΔCt) (28) and presented as a fold change vs. 191 
conventional control group, or in the case of the FOS-inulin study, fold change vs. the 192 
middle-aged control mice. 193 
 194 
Statistical analysis  195 
Data were analysed using one-way ANOVA followed by Bonferroni’s test. A two-way 196 
ANOVA, with Bonferroni post hoc test for further analysis, was used to compare the effects 197 
of age and FOS-inulin on hepatic gene expression. The Grubbs method was employed to 198 
identify any outliers (29). The threshold for statistical significance was set at p<0.05. Data are 199 
expressed as mean +SEM. All statistical procedures were performed using GraphPad Prism 200 





Microbial colonisation significantly alters hepatic CYP and MDR expression in GF mice 204 
The expression of murine CYP drug-metabolising enzymes, Cyp2b10 and Cyp3a11, was 205 
markedly downregulated under GF conditions relative to conventional mice (p<0.001; Figure 206 
1 (A)). [see Figure 1] 207 
We further investigated whether colonisation could restore the expression of these two CYP 208 
drug-metabolising enzymes in GF mice. At the transcript level, Cyp2b10 expression in GF 209 
mice did not recover after exposure to a microbial environment while the expression of 210 
Cyp3a11 was normalised to conventional levels. Colonisation exerted a similar influence on 211 
Cyp2a4 expression, but the effect was not significant.   212 
Neither GF status nor colonisation altered the mRNA expression of Mdr1a (Figure 1(B)). The 213 
Mdr1b isoform was, however, upregulated in GF mice relative to conventional mice 214 
(p<0.01). Notably, colonisation of GF mice normalised Mdr1b expression to conventional 215 
levels. The direction and magnitude of the effect of the gut microbiota on host metabolism 216 
and transport are likely, therefore, to be specific not only to the hepatic gene but also to the 217 
isoform of that gene. 218 
 219 
Butyrate alters Cyp2b10 expression only in the presence of a complex microbiota 220 
Butyrate supplementation did not induce widespread changes in hepatic genes. In the 221 
presence of a complex microbiota, butyrate only had a significant effect on the hepatic 222 
expression of Cyp2b10 (2.85-fold higher relative to conventional mice; p<0.05). No 223 
significant differences were observed in the other CYP or MDR1 genes in conventional mice. 224 
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A secondary objective of the butyrate intervention study was to see if this microbial 225 
metabolite could restore the gene expression of the enzymes altered in GF mice. The mRNA 226 
expression of Cyp2b10 in GF mice, however, remained perturbed after butyrate 227 
supplementation relative to conventional mice (Figure 2(A)). Moreover, the expression of 228 
Cyp3a11 in GF mice also remained extensively downregulated after butyrate 229 
supplementation relative to the corresponding conventional group (p<0.01; p<0.001, 230 
respectively). Butyrate, however, exerted an inhibitory effect on the expression of MDR1 231 
(Figure 2(B)). Butyrate decreased the expression of Mdr1a in GF mice (p<0.05) relative to 232 
the butyrate-treated conventional group, despite no evident changes in this isoform under GF 233 
conditions or by colonisation. Mdr1b expression remained marginally elevated, but not 234 
significantly so, after butyrate supplementation relative to conventional counterparts. [see 235 
Figure 2] 236 
To assess if butyrate had a broader impact on the CYP superfamily of enzymes, the mRNA 237 
expression of members of the Cyp-2c, -2d, and -2e families was further investigated. 238 
Notably, the expression of these enzymes was not affected by butyrate supplementation, 239 
regardless of the microbial status of the mice (Table S2).  240 
 241 
The impact of FOS-inulin on hepatic CYP and MDR expression is gene-specific and 242 
age-dependant 243 
Subsequently, we assessed whether the hepatic expression of CYP and MDR1 genes could be 244 
manipulated by modulating the gut microbiota with a prebiotic mix in young adult versus 245 
middle-aged mice. 246 
A significant interaction was identified between age and prebiotic in dictating the expression 247 
of Cyp2a4 (p<0.05; F (1,34) =4.216) (Figure 3(A)). In Cyp2a4, age affected the response to 248 
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FOS-inulin; Cyp2a4 gene expression was significantly upregulated in young-adult treated 249 
relative to middle-aged treated mice (p<0.01). 250 
Age and FOS-inulin did not alter Cyp2b10 expression. As no significant difference was 251 
evident in Cyp3a11 expression, the impact of diet-enriched with 10% FOS-inulin on the other 252 
CYP3A4/5 equivalent mouse isoform, Cyp3a13, was also investigated. For both Cyp3a13 253 
and Mdr1a, a significant interaction between age and prebiotic was observed [(p<0.05; F 254 
(1,35 =5.159), (p<0.01; F (1,32) =11.00) respectively]. Bonferroni’s multiple comparisons 255 
test revealed a significant downregulation of Cyp3a13 in young adult mice (p<0.05) and the 256 
prebiotic mix upregulated hepatic Mdr1a expression in young adults (p<0.05). As evident in 257 
Figure 3(B), the prebiotic mix did not elicit a significant effect on Mdr1a in middle-aged 258 
mice. Interestingly, the age-related impact on Mdr1a was opposite to the FOS-inulin induced 259 
upregulation in young mice (p<0.05).  Conversely, increasing age was coupled with 260 
decreased Mdr1b expression (p<0.05). [see Figure 3] 261 
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Discussion  262 
The implications of microbiome research for therapeutic interventions requires, in part, a 263 
mechanistic and predictive understanding of clinically-relevant microbiome-drug interactions 264 
(30, 31). Whilst most research to date on microbial-mediated metabolism of drugs largely 265 
centred around direct interactions between the drug substance and a microbe within the 266 
bacterial-dense colon (32), the research presented herein highlights the underappreciated 267 
indirect mechanisms by which the microbiota can dictate host metabolism in the liver. Here 268 
we further validated the modulation of CYP enzymes and MDR1 by the gut microbiome and 269 
illustrated the altered expression of hepatic genes in GF animals that can be rescued, in some 270 
cases, by colonisation. The overall impact of butyrate and prebiotic supplementation on host 271 
gene expression cannot be generalised. Butyrate and FOS-inulin only modify the hepatic 272 
expression of certain enzymes in a context and time-dependent manner. Neither intervention 273 
exerted a consistent effect across all enzymes and transporters investigated in this study. 274 
Given the gut microbiome is a complex ecosystem regularly exposed to a continually 275 
changing cocktail of small and large molecules (33), it is unlikely that a single metabolite, or 276 
prebiotic, could have a universal effect overall. There are likely to be a variety of pathways or 277 
metabolites involved in microbiome-host interactions that will contribute to inter-individual 278 
variability in drug metabolism and disposition. Our results may, however, provide the 279 
impetus to explore the potential of prebiotic supplementation to modify CYP and MDR1 280 
expression in a clinical setting 281 
Consistent with previous findings, GF conditions resulted in the most prominent changes in 282 
hepatic genes, most notably a downregulation in mRNAs of Cyp2b10 and Cyp3a11, and a 283 
substantial upregulation of Mdr1b. The colonisation of GF mice restored Cyp3a11 expression 284 
to conventional levels illustrating that Cyp3a11 may be particularly susceptible to changes in 285 
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the composition of the gut microbiota. This finding may have important clinical implications 286 
as Cyp3a11 is the murine equivalent gene of hCYP3A4/5. In particular, the hCYP3A gene 287 
family is responsible for the oxidation of approximately 50% of drugs (34). The normalized 288 
Cyp3a11 gene expression in the livers of colonised GF mice is consistent with previous 289 
studies using colonisation or secondary bile acid replacement approaches (8, 35, 36). In 290 
contrast to others (8), however, GF status substantially reduced Cyp2b10 in our study. 291 
Cyp2b10 is the murine equivalent gene of hCYP2B6, which is linked to the metabolism of 292 
anaesthetics and analgesics (37). However, a more recent study, using RNA-sequencing, by 293 
the same research group supported our finding of reduced Cyp2b10 in GF mice (38).  294 
Our study is the first to demonstrate a clear role of the gut microbiome on drug transporters. 295 
P-gp works in tandem with drug-metabolising enzymes, specifically CYP3A4/5, to reduce 296 
the oral bioavailability of certain drug molecules, which are substrates of both genes (39). 297 
Intestinal and hepatic drug transporters can dictate the amount of drug in the systemic 298 
circulation by influencing drug absorption from the gut lumen or by facilitating the evasion of 299 
drug metabolism on the first pass through the gut and liver. Factors affecting transporter 300 
function or expression may, therefore, be important determinants of drug pharmacokinetics 301 
(40). Our results illustrate that both murine isoforms of MDR1 are susceptible to microbiota-302 
related changes as evidenced by the induction of Mdr1b by GF conditions, or by the 303 
inhibitory effect of butyrate on Mdr1a and Mdr1b. Previously, colonisation with Bacteroides 304 
thetaiotaomicron downregulated Mdr1a expression in GF mice (41). Earlier research has also 305 
indicated a sex-related food effect on the protein level of intestinal P-gp in rats (42). The 306 
induction of Mdr1a expression by diet-enriched FOS-inulin in our study may provide further 307 
insights into the dietary impact on host P-gp expression levels.   308 
Overall, butyrate supplementation did not induce widespread changes in hepatic gene 309 
expression. Butyrate supplementation did not cause extensive changes in hepatic genes of 310 
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conventional mice except for Cyp2b210. In the case of GF mice, transcript levels of Cyp2b10 311 
remained downregulated even after butyrate supplementation, but this microbial metabolite 312 
had a significant inhibitory effect on Mdr1a expression in butyrate-treated GF mice relative 313 
to conventional counterparts. Butyrate-induced effects on hepatic genes, therefore, may 314 
depend on the microbial status of the host, highlighting the complexity of microbe-liver 315 
interactions, and the difficulty in extrapolating from GF animals to those with a conventional 316 
microbiota. Future studies employing a longer duration of butyrate supplementation or 317 
investigating the effect of alternative SCFAs (e.g., acetate, propionate) or a combination of 318 
SCFAs, may provide further mechanistic insight into the role SCFAs play in microbiome-319 
influenced host gene expression. Indeed, investigating the impact of different microbial 320 
metabolites, such as tryptophan and bile acids, on hepatic CYP expression may help to 321 
further delineate the molecular underpinnings of this host-microbe interaction. Moreover, the 322 
microbial regulation of the hepatic transcriptome has been linked to the circadian oscillations 323 
of serum metabolites which can affect the detoxification pattern in the liver (43), therefore, 324 
the impact of microbial metabolites at different times of the day also merits consideration. 325 
Fermentation of fibre is one of the primary sources of SCFAs. Diet-derived butyrate must 326 
also be considered in terms of experimental design as it may have implications for butyrate-327 
mediated physiological functions (44), albeit dietary sources may, however, be more 328 
important in small intestine where bacterial fermentation is lowest (45). Through regular 329 
monitoring of food intake across the butyrate-supplemented and non-treated groups, we 330 
confirmed no differences in the potential dietary sources of butyrate across all groups. 331 
Previous research has illustrated that the majority of SCFAs in the gut come from bacterial 332 
fermentation as has been reported previously with levels of 1020 mumol/kg in caecum of 333 
Norwegian GF mice vs levels of 124,600 mumol/kg in the caecum of conventional mice (45). 334 
Recently, our group illustrated that supplementation with the prebiotic mix, FOS-inulin, 335 
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altered propionate, and valerate levels in the caecum (21), further substantiating previous 336 
links between SCFAs and prebiotics (46-48). Our results suggest FOS-inulin-induced effects 337 
on hepatic gene expression are specific to the gene isoform. This prebiotic mix significantly 338 
altered Cyp3a13 and Mdr1a expression in the liver of young adult mice but exerted no 339 
influence on the Cyp3a11 or Mdr1b gene isoforms. Overall, FOS-inulin supplementation for 340 
14 weeks did not translate to marked differences in the expression of hepatic genes in 341 
conventional animals. Previously, a one-month treatment with a cocktail of probiotics, 342 
VSL#3, was also found insufficient to alter the hepatic expression of many drug-metabolising 343 
genes (8). It is plausible that microbiota-targeted interventions, including prebiotics and 344 
probiotics, may require extended chronic treatment to elicit more extensive changes in 345 
metabolic pathways under healthy or naïve conditions or that the effects may be contingent 346 
on the host, such as age or gender.  347 
As age is a well-established influential factor for drug metabolism capacity (4, 49-51), we, 348 
therefore, sought to explore whether the response to prebiotics was age-dependant. Increasing 349 
age is associated with an approximate 40-45% downregulation of detoxification enzymes 350 
(34). In this study, the specific life-stages of young adult and middle-aged were chosen to 351 
examine if the response to FOS-inulin depended on the age of the host while avoiding the 352 
confounding effect of old age-related decline in hepatic function (52). Like the prebiotic-353 
induced effects, age significantly modified the expression of CYP and MDR1 isoforms in an 354 
isoform-specific manner. Moreover, age dictated the impact of prebiotics on Cyp2a4, 355 
suggesting that age-related changes in hepatic CYP isoforms may influence the efficacy and 356 
safety of drugs. However, the effects of ageing on the expression and activity of CYP 357 
enzymes in humans remains controversial due to the many confounding factors, including 358 
concomitant diseases and personal medical history. 359 
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Overall, these results lend further support to the role the gut microbiota plays on host drug 360 
metabolism. To our knowledge, this study provides the first evidence on the influence the gut 361 
microbiota exerts on a drug-efflux transporter gene, MDR1. Having identified current gaps in 362 
our understanding of the mechanistic basis for these microbiome-liver interactions, the 363 
impact of butyrate supplementation on a much broader range of host drug-metabolising 364 
enzymes and transporters was investigated, extending to previous work on butyrate-induced 365 
changes specific to the Cyp1a family (14, 15). A limitation of the study herein is that data 366 
obtained on the mRNA level only hints on a general pattern of expression, and future studies 367 
should now focus on protein levels and enzyme activity to confirm the microbial regulation 368 
of these hepatic genes implicated in drug metabolism and transport. Herein, butyrate did not 369 
exert an extensive impact on a range of hepatic genes and research efforts may need to be 370 
shifted towards alternative microbial metabolites. Nonetheless, the study herein represents an 371 
important stepping stone for further studies exploring the microbiome-liver crosstalk. 372 
Furthermore, there is still uncertainty concerning the existence of species differences in genes 373 
implicated in drug metabolism and transport (27), and thus, there is a requirement for more 374 
studies in this area to establish a sound basis for correlation of preclinical studies to clinical 375 





This data further strengthens the increasing body of evidence linking the gut microbiota as a 379 
modulator of host gene expression, specifically in influencing hepatic enzymes involved in 380 
drug metabolism and disposition. Not only may the gut microbiota alter how the host 381 
metabolises drugs but may, through the modified efflux process from the liver to the bile 382 
duct, also influence the distribution and elimination process of drugs.  On a mechanistic level, 383 
it appears the microbial metabolite butyrate is not singularly involved in mediating these 384 
effects on host metabolism and transport. Butyrate-induced effects on CYP and P-gp 385 
expression are gene-specific and, even in some cases, dependent on the specific isoform of 386 
the gene, as evidenced by its impact on Cyp2b10 and MDR1 isoforms, respectively. Further 387 
studies are required to elucidate microbiota-induced changes in host gene expression at the 388 
protein level and to unravel the mechanistic basis for this crosstalk between the gut 389 
microbiome and the liver, including the impact of other SCFAs or different microbial 390 
metabolites such as tryptophan. Furthermore, prebiotic supplementation modulates host gene 391 
expression and may play a role in normalising metabolic activity or reducing inter-individual 392 
variability in drug pharmacokinetics.  393 
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Table 1. Overview of the human equivalent mouse CYP enzymes. The previously 563 
identified murine Cyps most similar or equivalent to human CYP enzymes, and examples of 564 





Substrate Drugs References 
Cyp1a2 CYP1A2 Chlorpromazine, Amitriptyline, Zolmitriptan  
 
 
(4, 53, 54) 
(a) 
Cyp2a4 CYP2A6 Letrozole, Nicotine, Nifedipine 
Cyp2b10 CYP2B6 Ketamine, Selegiline, Methadone 
Cyp3a11  
CYP3A4/5 




Digoxin, Verapamil, Domperidone, Ranitidine 














Figure 1. Microbial status alters mRNA expression of hepatic genes. (A) Relative mRNA 568 
expression of CYP450 drug-metabolising genes in the livers of germ-free (GF), colonised 569 
GF, and conventionally raised C57BL/6 mice. (B)  Relative mRNA expression of two murine 570 
isoforms of hMDR1, Mdr1a, and Mdr1b, in the livers of GF, colonised GF, and 571 
conventionally raised C57BL/6 mice. Data analysed by one-way ANOVA with Bonferronis’ 572 
multiple comparisons test and represented as mean + SEM (n=5-6). (* Conv. vs GF; # Conv. 573 
vs GF colonised; $ GF vs GF colonised; $ = p<0.05; **, p<0.01; ###, p<0.001; n=5-6/group). 574 
 575 
Figure 2. Impact of butyrate supplementation on hepatic genes. Relative mRNA 576 
expression of murine hepatic (A) CYP isoenzymes and (B) MDR1 transporter in 577 
conventionally raised and GF mice supplemented with sodium butyrate or sodium-matched 578 
saline (n=12-15/group). Data analysed by one-way ANOVA with Bonferronis’ multiple 579 
comparisons test and represented as mean + SEM. * p<0.05; ##, p<0.01; ###, p<0.001; Conv, 580 





Figure 3. FOS-inulin impact on hepatic gene expression. Relative mRNA expression of 584 
murine hepatic (A) CYP isoenzymes and (B) MDR1 transporter respectively in young and 585 
middle-aged conventionally raised male mice receiving chow supplemented with FOS-inulin 586 
or standard chow. Data analysed by two-way ANOVA and Bonferroni’s multiple 587 
comparisons test. Data represented as mean + SEM (n=9-10). (#or $, p<0.05; **, p<0.01). 588 
n=9-10/group.  589 
 
 
 
 
 
 
 
